Vident Advisory LLC Raises Position in GSK PLC Sponsored ADR $GSK

Key Points

• Vident Advisory LLC increased its stake in GSK PLC by 41.3%, owning 28,374 shares valued at approximately $1.1 million after acquiring an additional 8,294 shares.
• GSK reported **$1.23 EPS** for the last quarter, surpassing estimates of $1.12, while revenue reached **$10.64 billion**, exceeding the consensus estimate of **$7.92 billion**.
• The company has declared a quarterly dividend of **$0.4206 per share**, resulting in an annualized dividend yield of **4.3%**, with a current payout ratio of **77.78%**.

Vident Advisory LLC lifted its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 41.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,374 shares of the pharmaceutical company's stock after buying an additional 8,294 shares during the period. Vident Advisory LLC's holdings in GSK were worth $1,099,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Dodge & Cox boosted its position in shares of GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock worth $3,046,972,000 after acquiring an additional 10,210,921 shares during the last quarter. Voloridge Investment Management LLC raised its stake in GSK by 1,360.4% in the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock valued at $73,222,000 after acquiring an additional 2,016,795 shares during the period. Woodline Partners LP bought a new position in GSK in the fourth quarter valued at about $36,665,000. Miller Howard Investments Inc. NY lifted its holdings in shares of GSK by 138.4% in the 1st quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock worth $63,797,000 after purchasing an additional 955,891 shares in the last quarter. Finally, Kahn Brothers Group Inc. bought a new stake in shares of GSK during the 4th quarter valued at $29,921,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Down 1.3%

GSK stock traded down $0.54 during trading on Monday, hitting $39.97. 1,877,417 shares of the stock traded hands, compared to its average volume of 5,068,784. The stock has a market cap of $81.40 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 2.03 and a beta of 0.53. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.19. The firm's 50 day moving average is $38.51 and its two-hundred day moving average is $38.36. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same period in the prior year, the firm posted $0.43 earnings per share. The company's quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio is 77.78%.

Analyst Ratings Changes

Several research firms recently weighed in on GSK. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of "Reduce" and an average target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.